Previous 10 | Next 10 |
Summary MorphoSys AG is a German commercial-stage biopharmaceutical company founded in 1992 with more than 100+ pipeline candidates. We believe MorphoSys's two key value drivers are a) monjuvi and b) pelabresib. We expect Monjuvi's sales to continue to falter. There are no short...
Summary Canada offers a unique investment opportunity, with oligopolies dominating several sectors. Those sectors are financials, telcos, pipeline and utilities, grocers, and the railways. The wide moat portfolio has a history of a tremendous beat over the market, with less volatili...
Summary Genmab (GMAB) is a Danish commercial biopharma company with a leading technology and track record in innovative antibody-based therapeutics. Darzalex royalty revenue is the key driver of the stock price and the bedrock of Genmab's strong performance during 2021-2022. We expe...
Summary When I think about the lessons learned from 2022, I think the biggest lesson is valuations matter. I do think this is the most predicted recession that I've ever seen, certainly, in my career. Investors of all stripes, whether you're an asset allocator or a stock picker, I t...
Summary Royalty Pharma plc is an interesting investment fund that buys pharmaceutical royalties and generates a non-correlated yield. With the depressed biotech sector valuation and increasing cost of capital with rising interest rates, we expect explosive growth in deal-making for Roya...
Summary Gossamer's TORREY showed stat sig PVR improvement, but the 6MWD was under what investors were hoping for; this led to a +70% decline in share price. Seralutnib is entering phase 3 with an adapted design (with more severe patients); although the success is less clear, any positiv...
Summary Markets often turn well before the economy and we are starting to see Global PMIs stabilize. Like many other indicators, the market's "Pros and Cons" keep investors guessing. Investors are in the "glass half full" mindset. Negatives are placed on the back shelf now. Sent...
Summary Medical device stocks within the Health Care sector have seen some modest underperformance to kick off 2023. One firm reports results Thursday, and earnings growth is expected with ResMed as production ramps and margins should expand. With a bullish chart feature unfolding, ...
Summary Communication Services Select Sector SPDR Fund, which is up nearly 13% year-to-date. Current definition of communications includes firms that also fall under the heading of Big Tech – names such as Meta and Alphabet. At the moment, it’s fair to say that the bea...
Summary Among healthcare stocks, Eagle Pharmaceuticals is an interesting opportunity to benefit from volatility in stock markets. Eagle Pharmaceuticals' product portfolio continues to perform well and has the potential to strengthen its position in the market through new treatment devel...
News, Short Squeeze, Breakout and More Instantly...
SPDR Select Sector Fund - Health Care Company Name:
XLV Stock Symbol:
NYSE Market:
2024-07-09 10:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-29 11:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-09 09:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...